On Tuesday, Shares of BlackBerry Limited (NASDAQ:BBRY), surged 7.14% to $7.80.
BlackBerry Limited declared that WatchDox® by BlackBerry® has been named a “Visionary” in the Gartner Magic Quadrant1 for Enterprise File Synchronization and Sharing (EFSS) for the second successive year.
WatchDox by BlackBerry allows users to access documents from PC and Mac desktops, tablets, and smartphones, giving employees the flexibility to work across locations and be productive no matter where they are. WatchDox by BlackBerry is the most secure EFSS solution and is unique in that the document encryption and controls stay with the file even when it is shared on unmanaged devices. Users and administrators can track and audit who is accessing files and also have the ability to revoke access or delete files remotely. This gives organizations full visibility and control over how files are viewed, edited, copied, printed or forwarded.
WatchDox by BlackBerry stands out against other vendors in the EFSS space for its rich security and partnershipfeatures. It is known for its document encryption controls based on digital rights administration (DRM), extensive data protection and security capabilities counting geo-fencing, policy enforcements, and role-based access control, and extensive secure content editing capabilities that allow for productive collaboration. WatchDox by BlackBerry offers the most comprehensive EFSS solution, with content security capabilities that are Federal Information Processing Standard (FIPS) 140-2 certified by the U.S. government and utilize best-in-class AES 256-bit encryption for data-at-rest and data-in-transit. Built to meet the needs of enterprises with the highest security requirements, WatchDox by BlackBerry also offers flexibility in deployment models counting on-premise and hosted solutions.
BlackBerry Limited provides wireless communications solutions worldwide. The company offers BlackBerry wireless solutions, which comprise the sale of BlackBerry handheld devices; and the provision of data communication, and compression and security infrastructure services enabling BlackBerry handheld wireless devices to send and receive wireless messages and data.
Finally, CEL-SCI Corporation (NYSEMKT:CVM), ended its last trade with 13.29% surge, and closed at $0.64.
CEL-SCI Corporation declared it has added a second clinical site for its Phase I clinical trial evaluating peri-anal wart immunotherapy in HIV/HPV co-infected men and women with its investigational cancer immunotherapy Multikine* (Leukocyte Interleukin, Injection). Dr. Joel Palefsky, world renowned scientist and Key Opinion Leader (KOL) in human papilloma virus (HPV) research and the prevention of anal cancer, has joined the study as a Principal Investigator at the University of California San Francisco (UCSF). UCSF becomes the second clinical site for the study. The first site, the U.S. Naval Medical Center San Diego, continues to enroll patients under a Cooperative Research and Development Agreement (CRADA).
Dr. Joel Palefsky is the Chair of the HPV Working Group of the AIDS Malignancy Consortium (AMC) and is the head of the AMC HPV Virology Core Lab at UCSF. The AMC is a U.S. National Cancer Institute-supported clinical trials group founded in 1995 to support innovative trials for AIDS-related cancers. The AMC is composed of over 37 clinical trials sites worldwide, five Working Groups, an Administrative Office, a Statistical Office, and an Operations and Data Administration Office. Collectively, these components develop and oversee the scientific agenda, manage the groups’ portfolio of clinical trials and other scientific-based studies, and assist to develop new protocols. Dr. Palefsky has extensive experience in the biology of HPV infection, HPV infection in HIV-positive men and women, HPV vaccines and in the design and implementation of multiple clinical research trials of HPV-related disease.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company’s lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
